Develop DNDI-6174 as a new chemical entity for the treatment of visceral leishmaniasis with the aim of bringing an additional entity with a novel mechanism of action to the visceral leishmaniasis portfolio; and potentially for the treatment of cutaneous leishmaniasis
current phase of drug development
updated 15 Feb 2023
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019. DNDI-6174 presents a new mode of action among compounds in DNDi’s leishmaniasis portfolio, as well as a predicted low human dose and a very promising safety margin.
Get our latest news, personal stories, research articles, and job opportunities.